New pharma
Follow
Find
5.6K views | +1 today
New pharma
Pharma's struggle for a new commercial model
Curated by rob halkes
Your new post is loading...
Your new post is loading...
Scooped by rob halkes
Scoop.it!

Enormous value in 'appropriate use' of healthcare data - NEWS - articles - Pharmaceutical Industry - PMLiVE

Enormous value in 'appropriate use' of healthcare data - NEWS - articles - Pharmaceutical Industry - PMLiVE | New pharma | Scoop.it
Pharmaceutical Industry | NEWS | | Enormous value in 'appropriate use' of healthcare data - Report says governments, organisations and individuals could benefit from effective 'trade rules' for data | PMLiVE...
more...
No comment yet.
Rescooped by rob halkes from The Pharmaceutical Industry
Scoop.it!

World’s first stem cell drug approved in Canada | InPharm

World’s first stem cell drug approved in Canada | InPharm | New pharma | Scoop.it
Canada has approved the world’s first stem cell drug, marking an historic day for the burgeoning therapy.

 

Osiris' Prochymal is now approved in Canada in children with graft versus host disease (GvHD), a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient’s body.

 

Prochymal is made up of bone marrow stem cells derived from an adult donor and is designed to control inflammation, promote tissue regeneration and prevent scar formation – GvHD affects around 3,500 to 4,000 worldwide.

 

“Today, Osiris turns the promise of stem cell research into reality, delivering on decades of medical and scientific research,” said Peter Friedli, chairman and co-founder of Osiris.

 

“It took 20 years of hard work and perseverance and I want to personally thank everyone involved for their dedication to this important mission.”

The approval is based on recent trial results that showed statistically significant improvement in survival in patients taking Prochymal, when compared with a historical control population of children with refractory GvHD.

 

Andrew Daly, principal investigator in the Phase III programme for Prochymal, said: “I am very proud of the leadership role Canada has taken in advancing stem cell therapy and particularly gratified that this historic decision benefits children who would otherwise have little hope.

 

“As a result of Health Canada’s comprehensive review, physicians now have an off-the-shelf stem cell therapy in their arsenal to fight GvHD.

“Much like the introduction of antibiotics in the late 1920s, with stem cells we have now officially taken the first step into this new paradigm of medicine.”

It has not been an easy road for the firm - in 2009, two late-stage clinical trials failed to show the drug was more effective overall than a placebo in treating the disease.

 

But it did show promise in certain subgroups of patients, and the firm later re-analysed its data to confirm that its drug could increase survival in this patient population.

 

The Canadian regulators have told Osiris that it must carry out further testing on the drug after it reaches the market.

 

Osiris, which is based in Columbia, Maryland, plans to submit its drug with the FDA by the end of this year, including its newly analysed information.

 

Boost for stem cell research

 

Dozens of adult stem cell therapies are currently moving through clinical trials, and Canada’s approval of Prochymal will be a boost to many working in the field.

 

But the use of stem cells remains controversial, as some are derived from the cells of embryos.

However, stem cells derived from adult tissue such as fat or bone marrow – such as with Osiris’ drug - can get around these ethical concerns.

 

Osiris signed a pact potentially worth around $1.4 billion with Genzyme in 2008 to develop Prochymal and another stem cell drug, Chondrogen, for osteoarthritis.

 

But in February Genzyme, now a part of Sanofi, said it had discontinued its project with Prochymal for GvHD.


Via Thibaud Guymard
more...
No comment yet.
Rescooped by rob halkes from The Pharmaceutical Industry
Scoop.it!

Sales forces shrank in 2011, but not everywhere

Sales forces shrank in 2011, but not everywhere | New pharma | Scoop.it
Pharmas shrank their US sales forces by 7% between 2010 and 2011, but the pain wasn't shared evenly between the biggest of pharmas, as a number of players scaled up.

 

Roche cut deepest among big pharmas, lopping off a third of its Full-Time Rep Equivalents, while Abbott and Sanofi were close behind, downsizing 23% of their FTEs, according to an analysis by Cegedim Strategic Data. GSK cut its FTE force by 22% and Bayer by 19%.

 

But Boehringer Ingelheim and Novo Nordisk went on hiring sprees, bumping up their FTE numbers by 15% and 13%, respectively, while AstraZeneca and Warner Chilcott increased FTEs 11%. Amgen's FTE count was up a whopping 32%. A number of smaller and mid-sized pharmas were hiring, too, including Gilead, Endo, Elorac and Somaxon.

 

Driving hiring at AstraZeneca was promotion of Crestor, the nation's most-detailed brand in 2011 with around 2.5 million details. The next-most-detailed brands were Cymbalta and Bystolic, with 2.1 million details, followed by Celebrex and Seretide, with 1.9 million, Lipitor with 1.7 million, Spiriva with 1.6 million and Symbicort and Pradaxa with 1.5 million.

 

The average length of details declined again in 2011, to under 5 minutes. In 2007, 70% of details were over 5 minutes. Increasingly, said Cegedim, physicians' offices, under pressure from managed care and having increased patient volume to make up for less reimbursement, “are setting aside only a small, highly competitive window of time per week for details,” while others stop seeing reps altogether.

Complicating access for reps is the fact that their employers, seeking cost-savings, are pulling back on samples, which dropped again in 2011, while brochure leave-behinds increased. Reps armed with samples are more likely to get a foot in the door than those carrying only brochures, but samples are costly to companies.


Via Thibaud Guymard
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

ePharma Summit: Sit Down with an #ePharma West Guru: Scott ...

ePharma Summit: Sit Down with an #ePharma West Guru: Scott ... | New pharma | Scoop.it
In a heavily regulated industry like pharma, where other companies are hesitant to engage in social media because of the potential risks, Sanofi US is demonstrating that social media engagement can be highly successful, ...
more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

Growing support for co-creation between pharma and patients

Growing support for co-creation between pharma and patients | New pharma | Scoop.it

Support is growing for increased collaboration between pharmaceutical companies and patients in research processes worldwide, according to a new report by GBI Research


Via Andrew Spong
more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

Doctors who “Tablet Touch” during details have better iPad rep experiences

Doctors who “Tablet Touch” during details have better iPad rep experiences | New pharma | Scoop.it

A new manhattanResearch report suggests that physicians who touched a sales rep's iPad were more likely to have a satisfactory experience, and more likely to say the experience influenced their clinical decisions.

 

However, only one-quarter of the 30 percent of physicians who saw a sales rep with an iPad actually touched the device during the meeting.

 

[AS: a new chapter in the mythologising of the arcane, totemic qualities of the iPad as an influencer of physician behaviour is written with the release of this data.

 

What exactly is it about the way that content is presented by iOS which leads doctors to feel as though they have been more influenced than they would have done were it presented on either another tablet, or perhaps a laptop?

 

Is it the tactile nature of the experience? The ability of iOS to render graphics? Or a conditioned response on the part of the audience that associates the tablet with other experiences?

 

It is also interesting to note that reps seem unwilling to let the tablet out of their hands, and let the doctor 'drive' the detail. I would have thought '1. pass the iPad to the clinician' was the first item on the Successful Digital Detailing 101 training program.]


Via Andrew Spong
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

TweetPharm Pharma Social Media Infographic | Intouch Solutions

TweetPharm Pharma Social Media Infographic | Intouch Solutions | New pharma | Scoop.it

TweetPharm is a free interactive infographic that tracks pharmaceutical companies' use of Twitter.

more...
No comment yet.
Rescooped by rob halkes from 2- HEALTHCARE SOCIAL MEDIA by PHARMAGEEK
Scoop.it!

Youtube video Pharmaceutical Marketing: Social Media Monitoring by Google at Digipharm Europe Conference

Strategy for pharmaceutical marketing and communications professionals- presentations and video content from our events covering, digital, mobile and social ...


Via Thierry Le Magny, Lionel Reichardt / le Pharmageek
more...
Auvaro Philippe's comment, May 1, 2012 9:44 PM
Merci beaucoup; c'est dommage que Jens soit oblige d'accelerer vers la fin. Peut-on avoir acces a ses slides sur un post de la conference?
Scooped by rob halkes
Scoop.it!

Pharma social media directory - Digital Handbook - Social media

Pharma social media directory - Digital Handbook - Social media | New pharma | Scoop.it

- PMLiVE... pharma social media directory

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

When no news is bad news - Medical Marketing and Media

When no news is bad news - Medical Marketing and Media | New pharma | Scoop.it

When no news is bad newsMedical Marketing and MediaBut guess what? Very few people outside of pharma are even aware of these issues. Even if they were, chances are they wouldn't care. So perhaps it's time to stop assuming that they do.

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Survey: Pharma lags peers in gaining trust via social media - FierceBiotechIT

Survey: Pharma lags peers in gaining trust via social media - FierceBiotechIT | New pharma | Scoop.it

Survey: Pharma lags peers in gaining trust via social media

Read more: Survey: Pharma lags peers in gaining trust via social media - FierceBiotechIT http://www.fiercebiotechit.com/story/survey-pharma-lags-peers-gaining-trust-social-media/2012-04-23#ixzz1ssxf5LNn
Subscribe: http://www.fiercebiotechit.com/signup?sourceform=Viral-Tynt-FierceBiotechIT-FierceBiotechIT

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Programme - Day One Wednesday 25th April | Mobile Pharma

Programme - Day One Wednesday 25th April | Mobile Pharma | New pharma | Scoop.it
Programme - Day One Wednesday 25th April - Addressing how to mobilise healthcare content to engage and provide information to your stakeholders.
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

The industry’s top 20 #pharmaceutical marketing trends - DigiPharm - Digital Marketing Strategies for Pharmaceutical Products

The industry’s top 20 #pharmaceutical marketing trends - DigiPharm - Digital Marketing Strategies for Pharmaceutical Products | New pharma | Scoop.it
excerpt: We are launching a great new pharma marketing event this year that will run alongside DigiPharm, the Pharma Marketing Show. I’ve been working on putting the agenda and speaker panel together over the last couple of months..
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

The end of drug discovery?

The end of drug discovery? | New pharma | Scoop.it
As budgets are cut and many of the pharmaceutical industry's most lucrative drugs come off patent, will the drug industry be able to make the medicines for the future?
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma marketing research and Web 2.0 | eyeforpharma

Pharma marketing research and Web 2.0 | eyeforpharma | New pharma | Scoop.it
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Should Pharma Go Culture Casting?

Should Pharma Go Culture Casting? | New pharma | Scoop.it
The current pharma landscape still doesn't offer guidelines for social media participation, but it's not stopping patients from talking and influencing their networks. Going culture casting and enlisting the help of the most ...
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Steven Burrill: Can Pharma Turn the Oceanliner Around? | PharmaQbD

Steven Burrill: Can Pharma Turn the Oceanliner Around? | PharmaQbD | New pharma | Scoop.it
To survive, the biotech guru says, Big Pharma must ignore the “gravel in the road” and continue driving towards personalized medicine.
more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

Thinking of having a website as the hub of your next campaign to educate doctors? Don't bother

Thinking of having a website as the hub of your next campaign to educate doctors? Don't bother | New pharma | Scoop.it

Just 10 percent of doctors prefer to receive information via pharma websites.

 

A slide excerpted from a Doctors.net.uk presentation by Jo Bell and Tim Ringrose, available here (PDF):

 

http://www.pharmatimes.com/Libraries/web_SOPHIE_docs/Tim_Ringrose_doctors_net_CIRCULATION_slides_1.sflb.ashx


Via Andrew Spong
more...
Sven Awege's comment, May 5, 2012 12:36 AM
How neutral is the audience if they are answering the question on a community platform. Manhattan gives a more representative view.
Clearly Pharma sites do not have same objectives. HCP would not expect to need the Pharma site on a weekly, or even monthly basis, but 3 or 4 times a year might be what good looks like! I'm not a big fan of Pharma sites, but I do wish we'd stop comparing apples with pears!
What does come out of this is that Pharma needs to produce higher quality content or solutions, and work on building more trust through true engagement.
Scooped by rob halkes
Scoop.it!

Study reveals scale of errors on doctors' prescriptions - The Guardian

Study reveals scale of errors on doctors' prescriptions - The Guardian | New pharma | Scoop.it
The GuardianStudy reveals scale of errors on doctors' prescriptionsThe GuardianA study commissioned by the GMC, which regulates doctors, found that over the course of a year, one in 20 prescription items had some sort of error or monitoring of the...
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma Report 2012 Get Back in Shape

Pharma Report 2012 Get Back in Shape | New pharma | Scoop.it
When big pharma looks in the mirror, what does it see A body beset by old, expiring brands and not enough energetic, youthful ones to replace them.
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

201: Social Media for Health | iQ the innovation lab of GSW Worldwide

201: Social Media for Health | iQ the innovation lab of GSW Worldwide | New pharma | Scoop.it
Two years ago, we created a Social Media 101 class – basically, a bootcamp for pharma marketers who wanted to understand how social media was changing how (RT @iQLab: Social Media for Health: A 201 level look at state of social media in healthcare...
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Survey of Lupin Sales Force Finds Increased Managed Care Knowledge Leads to Greater Effectiveness Through Maestro Lite from BusinessOne Technologies | Business Wire

Survey of Lupin Sales Force Finds Increased Managed Care Knowledge Leads to Greater Effectiveness Through Maestro Lite from BusinessOne Technologies | Business Wire | New pharma | Scoop.it
A recent survey of 140 Lupin Pharmaceuticals, Inc., field sales reps and district managers assessing the impact of BusinessOne Technologies, Inc.&rsqu...
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Survey: Pharma lags peers in gaining trust via social media - FierceBiotechIT

Survey: Pharma lags peers in gaining trust via social media - FierceBiotechIT | New pharma | Scoop.it

Survey: Pharma lags peers in gaining trust via social media

Read more: Survey: Pharma lags peers in gaining trust via social media - FierceBiotechIT http://www.fiercebiotechit.com/story/survey-pharma-lags-peers-gaining-trust-social-media/2012-04-23#ixzz1ssxf5LNn
Subscribe: http://www.fiercebiotechit.com/signup?sourceform=Viral-Tynt-FierceBiotechIT-FierceBiotechIT

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Five ways pharma uses social media - Digital Handbook - Social media

Five ways pharma uses social media - Digital Handbook - Social media | New pharma | Scoop.it
All the top 10 pharma companies use social media, here's how  - PMLiVE...
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

How can pharma better interact with patient communities? | pharmaphorum

How can pharma better interact with patient communities? | pharmaphorum | New pharma | Scoop.it
This is an article about how pharma can better interact with patient communities.
more...
No comment yet.